Imaging modalities in synchronous oligometastatic prostate cancer.

Details

Ressource 1Download: 30069582_BIB_0AE3D10E4255.pdf (1325.75 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_0AE3D10E4255
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Imaging modalities in synchronous oligometastatic prostate cancer.
Journal
World journal of urology
Author(s)
Futterer J.J., Surcel C., van den Bergh R., Borgmann H., Briganti A., Gandaglia G., Kretschmer A., Ost P., Sooriakumaran P., Tilki D., Valerio M., Ploussard G., De Visschere PJL, Tsaur I.
Working group(s)
EAU-YAU Prostate Cancer Working Party
ISSN
1433-8726 (Electronic)
ISSN-L
0724-4983
Publication state
Published
Issued date
12/2019
Peer-reviewed
Oui
Volume
37
Number
12
Pages
2573-2583
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Along with a number of other malignancies, the term "oligometastatic" prostate cancer has recently emerged. It represents an attempt to define a subtype of cancer with a limited metastatic load that might perform more favorably than a distinctly disseminated disease, or even one that may be managed in a potentially curative way. Since there is currently a knowledge gap of what imaging modalities should be utilized to classify patients as having this type of tumor, we aimed to shed light on the role of conventional and marker-based imaging in the setting of synchronous oligometastatic prostate cancer as well as summarize the available evidence for its clinical application.
A literature search on December 15th 2017 was conducted using the Pubmed database.
Functional imaging techniques like <sup>68</sup> Ga PSMA. <sup>68</sup> Ga PSMA PET-CT has currently been shown the best detection rates for the assessment of nodal, bone and visceral metastases, especially for smaller lesions at low PSA levels.
Functional imaging helps detect low-burden disease metastatic patients. However, these imaging modalities are not available in every center and thus clinicians may be prone to prescribe systemic treatment rather than referring patients for cytoreductive treatments. We hope that the ongoing prospective trials will help guide clinicians in making a more personalized management of synchronous metastatic patients.
Keywords
Humans, Magnetic Resonance Imaging, Male, Multimodal Imaging, Neoplasm Metastasis/diagnostic imaging, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Prostatic Neoplasms/diagnostic imaging, Prostatic Neoplasms/pathology, Imaging, MRI, Oligometastatic, PET-CT, PSMA, Prostate cancer
Pubmed
Open Access
Yes
Create date
07/08/2018 8:40
Last modification date
13/01/2021 7:08
Usage data